RANTES AND MACROPHAGE INFLAMMATORY PROTEIN 1-ALPHA INDUCE THE MIGRATION AND ACTIVATION OF NORMAL HUMAN EOSINOPHIL GRANULOCYTES

被引:616
作者
ROT, A
KRIEGER, M
BRUNNER, T
BISCHOFF, SC
SCHALL, TJ
DAHINDEN, CA
机构
[1] INST CLIN IMMUNOL,CH-3010 BERN,SWITZERLAND
[2] SANDOZ GMBH,A-1235 VIENNA,AUSTRIA
[3] GENENTECH INC,SAN FRANCISCO,CA 94080
关键词
D O I
10.1084/jem.176.6.1489
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The cellular infiltrates of certain inflammatory processes found in parasitic infection or in allergic diseases consist predominantly of eosinophilic granulocytes, often in association with activated T cells. This suggests the existence of chemotactic agonists specific for eosinophils and lymphocyte subsets devoid of neutrophil-activating properties. We therefore examined four members of the intercrine/chemokine superfamily of cytokines (monocyte chemotactic peptide 1 [MCP-1], RANTES, macrophage inflammatory protein 1alpha [MIP-1alpha], and MIP-1beta), which do not activate neutrophils, for their ability to affect different eosinophil effector functions. RANTES strongly attracted normal human eosinophils by a chemotactic rather than a chemokinetic mechanism with a similar efficacy as the most potent chemotactic myeloid cell agonist, C5a. MIP-1alpha also induced eosinophil migration, however, with lower efficacy. RANTES and MIP-1alpha induced eosinophil cationic protein release in cytochalasin B-treated eosinophils, but did not promote leukotriene C4 formation by eosinophils, even after preincubation with interleukin 3 (IL-3), in contrast to other chemotactic agonists such as C5a and formyl-methionyl-leucyl-phenylalanine (FMLP). RANTES, but not MIP-1alpha, induced a biphasic chemiluminescence response, however, of lower magnitude than C5a. RANTES and MIP-1alpha both promoted identical transient changes in intracellular free calcium concentration ([Ca2+]i), with kinetics similar to those induced by chemotactic peptides known to interact with G protein-coupled receptors. No cross-desensitization towards other peptide agonists (e.g., C5a, IL-8, FMLP) was observed, suggesting the presence of specific receptors. Despite its weaker eosinophil-activating properties, MIP-1alpha was at least 10 times more potent on a molar basis than RANTES at inducing [Ca2+]i changes. Interestingly, RANTES deactivated the MIP-1alpha-induced [Ca2+]i changes, while the RANTES response was preserved after MIP-1alpha stimulation. MCP-1, a potent monocyte chemoattractant and basophil agonist, as well as MIP-1beta, a peptide with pronounced homology to MIP-1alpha, did not activate the eosinophil functions tested. Our results indicate that RANTES and MIP-1alpha are crucial mediators of inflammatory processes in which eosinophils predominate.
引用
收藏
页码:1489 / 1495
页数:7
相关论文
共 30 条
[1]   MONOCYTE CHEMOTACTIC AND ACTIVATING FACTOR IS A POTENT HISTAMINE-RELEASING FACTOR FOR BASOPHILS [J].
ALAM, R ;
LETTBROWN, MA ;
FORSYTHE, PA ;
ANDERSONWALTERS, DJ ;
KENAMORE, C ;
KORMOS, C ;
GRANT, JA .
JOURNAL OF CLINICAL INVESTIGATION, 1992, 89 (03) :723-728
[2]   NEUTROPHIL-ACTIVATING PEPTIDE-1 INTERLEUKIN-8, A NOVEL CYTOKINE THAT ACTIVATES NEUTROPHILS [J].
BAGGIOLINI, M ;
WALZ, A ;
KUNKEL, SL .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (04) :1045-1049
[3]   AIRWAY EOSINOPHILS AND LYMPHOCYTES IN ASTHMA - BIRDS OF A FEATHER [J].
BERMAN, JS ;
WELLER, PF .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1992, 145 (06) :1246-1248
[4]   INTERLEUKIN-5 MODIFIES HISTAMINE-RELEASE AND LEUKOTRIENE GENERATION BY HUMAN BASOPHILS IN RESPONSE TO DIVERSE AGONISTS [J].
BISCHOFF, SC ;
BRUNNER, T ;
DEWECK, AL ;
DAHINDEN, CA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1990, 172 (06) :1577-1582
[5]   MONOCYTE CHEMOTACTIC PROTEIN-1 IS A POTENT ACTIVATOR OF HUMAN BASOPHILS [J].
BISCHOFF, SC ;
KRIEGER, M ;
BRUNNER, T ;
DAHINDEN, CA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 175 (05) :1271-1275
[6]  
BISCHOFF SC, 1992, BLOOD, V79, P2662
[7]   THE NEUTROPHIL-ACTIVATING PEPTIDE NAF/NAP-1 INDUCES HISTAMINE AND LEUKOTRIENE RELEASE BY INTERLEUKIN-3-PRIMED BASOPHILS [J].
DAHINDEN, CA ;
KURIMOTO, Y ;
DEWECK, AL ;
LINDLEY, I ;
DEWALD, B ;
BAGGIOLINI, M .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (05) :1787-1792
[8]  
FREW AJ, 1991, CLIN EXP IMMUNOL, V84, P270
[9]  
FREW AJ, 1990, J ALLERGY CLIN IMMUN, V85, P422
[10]  
GRONHOJLARSEN C, 1989, SCIENCE, V243, P1464